Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma

University of Wisconsin, Madison22 enrolled

Overview

rituximab and modified (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years

rituximab and modified hyperfractionated cyclophosphamide, vincristine doxorubicin, dexamethasone (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Mantle Cell Lymphoma

Interventions

modified Hyper-CVADDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Untreated mantle cell lymphoma Exclusion Criteria: * Pregnant or breast feeding

Locations (1)

UWCCC

Madison, Wisconsin, United States

Outcomes

Primary Outcomes

Complete Response Rate to Induction Therapy

Outcome is the % of subjects who achieved a Complete Response (CR) or Complete Response Unconfirmed (CRu) after induction therapy, following the Cheson et al criteria for standardized response criteria (1999).

Time frame: Median follow up of 37 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.